What happened?
A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Patient monitoring company iRhythm (NASDAQ: IRTC) jumped 8%. Is now the time to buy iRhythm? Access our full analysis report here, it’s free.
- Medical devices & supplies - cardiology, neurology, vascular company ICU Medical (NASDAQ: ICUI) jumped 8.2%. Is now the time to buy ICU Medical? Access our full analysis report here, it’s free.
- Medical devices & supplies - specialty company Globus Medical (NYSE: GMED) jumped 9.4%. Is now the time to buy Globus Medical? Access our full analysis report here, it’s free.
- Medical devices & supplies - specialty company Enovis (NYSE: ENOV) jumped 16%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
- Surgical equipment & consumables - diversified company CONMED (NYSE: CNMD) jumped 12.9%. Is now the time to buy CONMED? Access our full analysis report here, it’s free.
Zooming in on Enovis (ENOV)
Enovis’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. But moves this big are rare even for Enovis and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock gained 15% on the news that the Centers for Medicare & Medicaid Services reversed previously announced reimbursement cuts for the company's non-invasive bone growth stimulators. The decision marks a significant rebound for the stock, which had declined 12% during a prior session. The positive move was also supported by broader strength in the healthcare sector. According to reports, healthcare was the top-performing sector in the S&P 500 after a soft June jobs report dampened expectations for interest rate hikes, boosting defensive sectors.
Enovis is down 7.9% since the beginning of the year, and at $24.42 per share, it is trading 22.5% below its 52-week high of $31.51 from November 2025. Investors who bought $1,000 worth of Enovis’s shares 5 years ago would now be looking at only $154.29.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
